The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year after Novo Holdings’ $16.5 billion acquisition.

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not ...

It faces more than 1,800 lawsuits consolidated in federal court in Pennsylvania and new claims emerging weekly, according to ...

Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, Reuters writes ...

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation - a common heart rhythm condition - in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® da ...

Novo Nordisk is to freeze hiring in an effort to control costs at the drug maker. The halt will apply across all markets and ...

A host of women have complained that they are experiencing 'Ozempic vulva' after taking weight loss drugs to shed the pounds.

A doctor has revealed the truth behind what is being dubbed the 'Ozempic vulva' as the drug surges in popularity.

The weight loss drug, which was previously also used to treat diabetes, may be having an unexpected impact on a rather sensitive body part ...

COPENHAGEN, DENMARK (Reuters) -Wegovy-maker Novo Nordisk has implemented a global hiring freeze, which covers job roles that ...